Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Double-blind, Active-controlled Parallel Group Efficacy and Safety Study of BI 1356 ( 5.0 mg, Administered Orally Once Daily) Compared to Glimepiride Over Two Years in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Metformin Therapy
Brief Summary: The objective of the current study is to investigate the efficacy, safety and tolerability of BI 1356 (5.0 mg daily) compared to glimepiride given for 104 weeks as add-on therapy to preferably \> 1500 mg metformin in patients with type 2 diabetes mellitus with insufficient glycaemic control


Options:
A: Arm Label: Saxagliptin, 5 mg + insulin; Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin, 5 mg + insulin | Arm Label: Placebo + insulin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo + insulin | Intervention Type: DRUG; Name: Saxagliptin, 5 mg + insulin; Assigned to Arm(s): Saxagliptin, 5 mg + insulin | Intervention Type: DRUG; Name: Placebo + insulin; Assigned to Arm(s): Placebo + insulin
B: Arm Label: BI 1356 5mg, once daily; Type: EXPERIMENTAL; Interventions: Drug: Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mg, Drug: BI 1356 | Arm Label: Glimepiride; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo identical to BI 1356 5mg, Drug: Glimepiride | Intervention Type: DRUG; Name: Placebo identical to BI 1356 5mg; Assigned to Arm(s): Glimepiride | Intervention Type: DRUG; Name: Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mg; Assigned to Arm(s): BI 1356 5mg, once daily | Intervention Type: DRUG; Name: BI 1356; Assigned to Arm(s): BI 1356 5mg, once daily | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Glimepiride
C: Arm Label: Canagliflozin 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin, Drug: Metformin immediate release | Arm Label: Canagliflozin 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin, Drug: Metformin immediate release | Arm Label: Sitagliptin 100 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sitagliptin, Drug: Metformin immediate release | Arm Label: Placebo/Sitagliptin; Type: OTHER; Interventions: Drug: Placebo, Drug: Sitagliptin, Drug: Metformin immediate release | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/Sitagliptin | Intervention Type: DRUG; Name: Canagliflozin; Assigned to Arm(s): Canagliflozin 100 mg, Canagliflozin 300 mg | Intervention Type: DRUG; Name: Sitagliptin; Assigned to Arm(s): Placebo/Sitagliptin, Sitagliptin 100 mg | Intervention Type: DRUG; Name: Metformin immediate release; Assigned to Arm(s): Canagliflozin 100 mg, Canagliflozin 300 mg, Placebo/Sitagliptin, Sitagliptin 100 mg
D: Arm Label: Liraglutide; Type: EXPERIMENTAL; Interventions: Drug: liraglutide, Drug: placebo | Arm Label: Glibenclamide; Type: ACTIVE_COMPARATOR; Interventions: Drug: glibenclamide, Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutide | Intervention Type: DRUG; Name: glibenclamide; Assigned to Arm(s): Glibenclamide | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Glibenclamide | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Liraglutide

Answer: B